Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Anteris Technologies is known for its biomimetic transcatheter heart valve, the DurAVR THV System. The device is the first of its kind and has gained considerable attention as the TAVR market continues to grow.
Abbott pointed to double-digit growth for its Navitor TAVR valve as well as big gains for the TriClip and MitraClip devices. The company also shared positive sales figures for its EP, heart failure and rhythm management portfolios.
Images of the Globe Pulsed Field System courtesy of Kardium.
The Globe Pulsed Field System, which secured FDA approval in September 2025, features high-density mapping capabilities and a 122-electrode spherical array.
Johnson & Johnson reported $24.6 billion in sales for the fourth quarter of 2025, up 9.1% from the previous year. On an earnings call with investors, the company's CEO sang the praises of the company's cardiovascular health division.
The diet, named after the traditional eating habits of Greece and Italy, is already known for its benefits to the general public. Its impact on heart patients, however, was less clear.
Mount Sinai Hospital in New York is now using AI-powered virtual agents to call some patients before cath lab procedures. The move was designed to help nurses focus more on patient care and reduce their risk of burnout.
